Correlation of activated clotting time (ACT) with rFVIIa infusion and clinical efficacy in a patient with Glanzmann thrombasthenia and platelet alloantibodies

Thrombosis and Haemostasis

Volumn 87, Issue 6, 2002, Pages 1084-

  Ameri, Afshin ^a   Stolte, Scott ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 7; FIBRINOGEN RECEPTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN; THROMBOCYTE ANTIGEN;

BLOOD CLOTTING; BLOOD CLOTTING TIME; CASE REPORT; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; EPISTAXIS; FEMALE; GLANZMANN DISEASE; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; LABORATORY TEST; LETTER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; THROMBOCYTE ACTIVATION; THROMBOCYTE DISORDER; TONSIL DISEASE; BLOOD; CHILD; DRUG CONTRAINDICATION; DRUG EFFECT; IMMUNOLOGY; THROMBOCYTE TRANSFUSION;

ANTIGENS, HUMAN PLATELET; BLOOD COAGULATION; CHILD; FACTOR VIIA; HUMANS; ISOANTIBODIES; PLATELET TRANSFUSION; RECOMBINANT PROTEINS; THROMBASTHENIA; WHOLE BLOOD COAGULATION TIME;

EID: 0036282557     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613141     Document Type: Letter

References (4)

1. Glanzmann's thrombasthenia: The spectrum of clinical disease
2. Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient
3. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies
4. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia